Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease?

American Journal of Kidney Diseases

Volumn 45, Issue 1, 2005, Pages 136-147

  Kausz, Annamaria T ^b   Solid, Craig ^a   Pereira, Brian J G ^b   Collins, Allan J ^a   St Peter, Wendy ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Anemia; comorbidity; dialysis

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR EFFECT; CATHETER; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DISEASE MARKER; FEMALE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOMES RESEARCH; TIME PERCEPTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; COHORT STUDIES; COMORBIDITY; ERYTHROPOIETIN, RECOMBINANT; ETHNIC GROUPS; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 11144343632     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.08.042     Document Type: Article

References (29)

1. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease Update 2000 Am J Kidney Dis 37 suppl 1 2001 S182 S236
2. H. Xia, J. Ebben, J. Ma, A. Collins Hematocrit levels and hospitalization risk in hemodialysis patients J Am Soc Nephrol 10 1999 1309 1316
3. N. Ofsthun, J. Labrecque, E. Lacson, M. Keen, J.M. Lazarus The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients Kidney Int 63 2003 1908 1914
4. The National Institutes of Health US Renal Data System Clinical indicators and preventive care, in USRDS 2003 Annual Data Report 2003 National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD 87 102
5. A. Levin, J. Singer, C.R. Thompson, H. Ross, M. Lewis Prevalent left ventricular hypertrophy in the predialysis population Identifying opportunities for intervention Am J Kidney Dis 27 1996 347 354
6. A. Levin How should anemia be managed in pre-dialysis patients? Nephrol Dial Transplant 14 suppl 2 1999 S66 S74
7. R.N. Foley, P.S. Parfrey, J.D. Harnett, G.M. Kent, D.C. Murray, P.E. Barre The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease Am J Kidney Dis 28 1996 53 61
8. G.M. London, B. Zins, B. Pannier Vascular changes in hemodialysis patients in response to recombinant human erythropoietin Kidney Int 36 1989 878 882
9. J. Silberberg, N. Racine, P. Barre, A.D. Sniderman Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin Can J Cardiol 6 1990 1 4
10. J. Pascual, J.L. Teruel, J.L. Molla, F. Liano, M. Jimenez-Mena, J. Ortuno Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis A prospective study Clin Nephrol 35 1991 280 287
11. G. Cannella, G. La Canna, M. Sandrini Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic uremic patients Nephrol Dial Transplant 6 1991 31 37
12. S.K. Fellner, R.M. Lang, A. Neumann, C. Korcarz, K.M. Borow Cardiovascular consequences of the correction of the anemia of renal failure with erythropoietin Kidney Int 44 1993 1309 1315
13. R. Foley, P. Parfrey, J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 2000 1325 1335
14. J.W. Eschbach, T. Aquiling, N.R. Haley, M.H. Fan, C.R. Blagg The long-term effects of recombinant human erythropoietin on the cardiovascular system Clin Nephrol 38 suppl 1 1992 S98 S103
15. H. Furuland, T. Linde, J. Ahlmen, A. Christensson, U. Strombom, B. Danielson A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients Nephrol Dial Transplant 18 2003 353 361
16. D.N. Churchill, N. Muirhead, M. Goldstein Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients Clin Nephrol 43 1995 184 188
17. F. Madore, E. Lowrie, C. Brugnara Anemia in hemodialysis patients Variables affecting this outcome predictor J Am Soc Nephrol 8 1997 1921 1929
18. A. Collins, J. Ebben, J. Ma, W. Manning Hematocrit levels and associated Medicare expenditures Am J Kidney Dis 36 2000 282 293
19. J. Ma, J. Ebben, H. Xia, A. Collins Hematocrit level and associated mortality in hemodialysis patients J Am Soc Nephrol 10 1999 610 619
20. F. Locatelli The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity The experience of Lombardy Dialysis Registry Nephrol Dial Transplant 13 1998 1642 1644
21. A. Collins, S. Li, W. St. Peter Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% J Am Soc Nephrol 12 2001 2465 2473
22. G. Obrador, T. Roberts, W.S. Peter, E. Frazier, B. Pereira, A. Collins Trends in anemia at initiation of dialysis in the United States Kidney Int 60 2001 1875 1884
23. D. VanWyck, J. Stivelman, J. Ruiz, L. Kirlin, M. Katz, D. Ogden Iron status in patients receiving erythropoietin for dialysis-associated anemia Kidney Int 35 1989 712 716
24. J.W. Eschbach The anemia of chronic renal failure Pathophysiology and the effects of recombinant erythropoietin Kidney Int 35 1989 134 148
25. National Kidney Foundation DOQI Clinical Practice Guidelines for Vascular Access Am J Kidney Dis 30 suppl 3 1997 S150 S191
26. A. Besarab, R.P. Ross, T.J. Nasca The use of recombinant human erythropoietin in predialysis patients Curr Opin Nephrol Hypertens 4 1995 155 161
27. F. Valderrabano Erythropoietin in chronic renal failure Kidney Int 50 1996 1373 1391
28. N. Ismail, B.N. Becker An opportunity to intervene Erythropoietin for the treatment of anemia in pre-dialysis patients Nephrol Dial Transplant 13 1998 14 17
29. A. Collins, S. Li, J. Adamson, D. Gilbertson Assessment of pure red blood cell aplasia in US dialysis patients The limits of the Medicare data Am J Kidney Dis 43 2004 464 478